Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results